sábado, 21 de noviembre de 2026

FDA rejects Capricor Therapeutics’ Duchenne therapy, a decision that was a long time coming A public pressure campaign couldn’t alter the hard reality: The drug didn’t work

https://www.statnews.com/2026/11/20/fda-rejects-capricor-duchenne-therapy/ By Adam FeuersteinNov. 20, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.

No hay comentarios: